We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY - Free Report) closed the latest trading day at $51.22, indicating a +0.02% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.04%. Elsewhere, the Dow saw an upswing of 0.14%, while the tech-heavy Nasdaq depreciated by 0.03%.
The biopharmaceutical company's shares have seen an increase of 5.11% over the last month, not keeping up with the Medical sector's gain of 5.57% and the S&P 500's gain of 5.28%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on February 2, 2024. The company's upcoming EPS is projected at $1.73, signifying a 4.95% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $11.14 billion, indicating a 2.31% decline compared to the corresponding quarter of the prior year.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $7.51 per share and revenue of $44.67 billion. These results would represent year-over-year changes of -2.47% and -3.22%, respectively.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.32% lower. Bristol Myers Squibb currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Bristol Myers Squibb is at present trading with a Forward P/E ratio of 6.81. This denotes a discount relative to the industry's average Forward P/E of 17.99.
Investors should also note that BMY has a PEG ratio of 2.17 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 2 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Bristol Myers Squibb (BMY - Free Report) closed the latest trading day at $51.22, indicating a +0.02% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.04%. Elsewhere, the Dow saw an upswing of 0.14%, while the tech-heavy Nasdaq depreciated by 0.03%.
The biopharmaceutical company's shares have seen an increase of 5.11% over the last month, not keeping up with the Medical sector's gain of 5.57% and the S&P 500's gain of 5.28%.
The investment community will be paying close attention to the earnings performance of Bristol Myers Squibb in its upcoming release. The company is slated to reveal its earnings on February 2, 2024. The company's upcoming EPS is projected at $1.73, signifying a 4.95% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $11.14 billion, indicating a 2.31% decline compared to the corresponding quarter of the prior year.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $7.51 per share and revenue of $44.67 billion. These results would represent year-over-year changes of -2.47% and -3.22%, respectively.
Any recent changes to analyst estimates for Bristol Myers Squibb should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.32% lower. Bristol Myers Squibb currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Bristol Myers Squibb is at present trading with a Forward P/E ratio of 6.81. This denotes a discount relative to the industry's average Forward P/E of 17.99.
Investors should also note that BMY has a PEG ratio of 2.17 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 2 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.